{
    "clinical_study": {
        "@rank": "3307", 
        "arm_group": [
            {
                "arm_group_label": "G-Pump\u2122 (glucagon infusion)", 
                "arm_group_type": "Experimental", 
                "description": "G-Pump\u2122 (glucagon infusion); single subcutaneous infusion of each of 0.3 \u03bcg/kg, 1.2 \u03bcg/kg, and 2.0 \u03bcg/kg"
            }, 
            {
                "arm_group_label": "Novo Nordisk GlucaGen\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Novo Nordisk GlucaGen\u00ae; single subcutaneous infusion of each of 0.3 \u03bcg/kg, 1.2 \u03bcg/kg, and 2.0 \u03bcg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the safety, speed of absorption, and onset of action\n      of G-Pump\u2122 (glucagon infusion) at three doses as compared to Novo GlucaGen\u00ae, all delivered\n      via an OmniPod\u00ae pump to patients with type 1 diabetes (DM1)."
        }, 
        "brief_title": "PK/PD Study With G-Pump (Glucagon Infusion) in DM1 Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypoglycemia", 
        "condition_browse": {
            "mesh_term": "Hypoglycemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females diagnosed with type 1 diabetes mellitus for at least 24 months\n\n          -  Current usage of subcutaneous insulin pump treatment\n\n          -  Age 18-65 years\n\n          -  C-peptide level < 0.5 ng/ml\n\n          -  Willingness to follow all study procedures, including attending all clinic visits\n\n          -  Subject has provided informed consent and has signed and dated an informed consent\n             form before any trial-related activities\n\n        Exclusion Criteria:\n\n          -  Pregnant and/ or Lactating: For women of childbearing potential: there is a\n             requirement for a negative urine pregnancy test and for agreement to use\n             contraception during the study and for at least 1 month after participating in the\n             study.\n\n          -  HbA1c >9.0%\n\n          -  Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)\n\n          -  Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic\n             synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum\n             bilirubin of over 2.0.\n\n          -  Hematocrit of less than or equal to 34%\n\n          -  Congestive heart failure, NYHA class II, III or IV\n\n          -  History of Coronary artery disease\n\n          -  Active foot ulceration\n\n          -  History of a cerebrovascular accident\n\n          -  Active alcohol abuse or substance abuse\n\n          -  Active malignancy, except basal cell or squamous cell skin cancers\n\n          -  Major surgical operation within 30 days prior to screening\n\n          -  Seizure disorder\n\n          -  Current administration of oral or parenteral corticosteroids\n\n          -  Use of an investigational drug within 30 days prior to screening\n\n          -  Bleeding disorder, treatment with warfarin, or platelet count below 50,000\n\n          -  Proliferative or severe non-proliferative retinopathy\n\n          -  Gastroparesis\n\n          -  Personal or family history of pheochromocytoma or disorder with increased risk of\n             pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)\n\n          -  Insulinoma\n\n          -  Allergies to glucagon or glucagon-like products, or any history of significant\n             hypersensitivity to glucagon or any related products.\n\n          -  Glycogen storage disease\n\n          -  Any concurrent illness, other than diabetes, that is not controlled by a stable\n             therapeutic regimen\n\n          -  Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.\n\n          -  Any reason the principal investigator deems exclusionary"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081001", 
            "org_study_id": "XSGO-201", 
            "secondary_id": "4R44DK096706-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "G-Pump\u2122 (glucagon infusion)", 
                    "Novo Nordisk GlucaGen\u00ae"
                ], 
                "description": "single subcutaneous infusion of each of 0.3 \u03bcg/kg, 1.2 \u03bcg/kg, and 2.0 \u03bcg/kg", 
                "intervention_name": "Novo Nordisk GlucaGen\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "G-Pump\u2122 (glucagon infusion)", 
                    "Novo Nordisk GlucaGen\u00ae"
                ], 
                "description": "single subcutaneous infusion of each of 0.3 \u03bcg/kg, 1.2 \u03bcg/kg, and 2.0 \u03bcg/kg", 
                "intervention_name": "G-Pump\u2122 (glucagon infusion)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hypoglycemia", 
            "Glucagon", 
            "Artificial Pancreas"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "branigad@ohsu.edu", 
                "last_name": "Deborah Branigan", 
                "phone": "503-418-9070"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97239"
                }, 
                "name": "Oregon Health & Science University"
            }, 
            "investigator": {
                "last_name": "Jessica Castle, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "COMPARISON OF PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF G-PUMP\u2122 (GLUCAGON INFUSION) VS GLUCAGEN\u00ae DELIVERED SUBCUTANEOUSLY TO SUBJECTS WITH TYPE 1 DIABETES (DM1)", 
        "overall_official": {
            "affiliation": "Oregon Health and Science University", 
            "last_name": "Jessica Castle, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety-related parameters include: Vital signs, physical exam, EKG, standard safety laboratory parameters and incidence of adverse events (AEs) as well as serious adverse events (SAEs)", 
                "measure": "To evaluate the safety and tolerability of G-Pump\u2122 (glucagon infusion)", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose until follow-up visit, an expected average time period of 3 weeks per subject."
            }, 
            {
                "description": "The onset of action will be assessed by the time to reach 50% of the maximum glucose concentration (TGLUCOSE-50%-early) and the speed of absorption will be assessed by the time to reach 50% of maximum glucagon concentration (TGLUCAGON-50%-early)", 
                "measure": "To evaluate the efficacy of G-Pump\u2122 (glucagon infusion)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 15 minutes before each injection until 3 hours post-injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081001"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetic parameters include:  AUCGLUCAGON 0-60, AUCGLUCAGON 0-120, AUCGLUCAGON 0-150, CGLUCAGON max, TGLUCAGON max, TGLUCAGON-50%-late", 
                "measure": "Pharmacokinetics:", 
                "safety_issue": "No", 
                "time_frame": "Approximately 15 minutes before each injection until 3 hours post-injection"
            }, 
            {
                "description": "AUCGLUCOSE 0-60, AUCGLUCOSE 0-120, AUCGLUCOSE 0-150, Glumax, TGLUCOSE max, TGLUCOSE-50%-late", 
                "measure": "Pharmacodynamic:", 
                "safety_issue": "No", 
                "time_frame": "Approximately 15 minutes before each injection until 3 hours post-injection"
            }, 
            {
                "description": "Infusion site discomfort as assessed using a 100 mm Visual Analog Scale (VAS) Infusion site discomfort assessed using a categorical (ordinal) infusion site discomfort verbal rating scale Erythema and or edema formation at site of infusion assessed using the Draize scale", 
                "measure": "Local Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "From 10 minutes post-injection until 3 hours post-injection"
            }
        ], 
        "source": "Xeris Pharmaceuticals", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Emissary International LLC", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Xeris Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}